Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam)

Journal of Controlled Release

Volumn 89, Issue 1, 2003, Pages 87-99

  Langston, Melissa V ^a   Ramprasad, Mysore P ^a   Kararli, Tugrul T ^b   Galluppi, Gerald R ^b   Katre, Nandini V ^a  

^a SkyePharma Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

Chimeric growth factor; Controlled delivery; Liposomal depot system; Sustained granulopoiesis

Indexed keywords

BIOCOMPATIBILITY; DRUG THERAPY; LIPIDS; PHARMACOKINETICS; PROTEINS;

SUSTAINED DELIVERY;

CONTROLLED DRUG DELIVERY;

GROWTH FACTOR; LERIDISTIM; LIPOSOME; MYELOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; LEUKOCYTE COUNT; LIPID COMPOSITION; MALE; NEUTROPHIL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SUSTAINED RELEASE FORMULATION; TIME;

EID: 0037437076     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00073-7     Document Type: Article

References (29)

1. Ganser A. Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. Curr. Opin. Hematol. 2:1995;204-209.
2. Heil G., Hoelzer D., Sanz M.A., Lechner K., Liu Yin J.A., Papa G., Noens L., Szer J., Ganser A., O'Brien C., Matcham J., Barge A. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood. 90:1997;4710-4718.
3. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., Depierre A., Johnson P., Decoster G., Tomita D., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer. 3:1993;319-324.
4. Eder M., Geissler G., Ganser A. IL-3 in the clinic. Stem Cells. 15:1997;327-333.
5. McWherter C.A., Feng Y., Zurfluh L.L., Klein B.K., Baganoff M.P., Polazzi J.O., Hood W.F., Paik K., Abegg A.L., Grabbe E.S., Shieh J.J., Donnelly A.M., McKearn J.P. Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin. Biochemistry. 38:1999;4564-4571.
6. Lee S.C., Ibdah R., Van Valkenburgh C., Rowold E., Abegg A., Donnelly A., Klover J., Merlin S., McKearn J.P. Phage display mutagenesis of the chimeric dual cytokine receptor agonist myelopoietin. Leukemia. 15:2001;1277-1285.
7. Monahan J.B., Hood W.F., Welply J.K., Shieh J.J., Polazzi J.O., Li X. Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors. Exp. Hematol. 29:2001;416-424.
8. MacVittie T.J., Farese A.M., Davis T.A., Lind L.B., McKearn J.P. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally X-irradiated non-human primates. Exp. Hematol. 27:1999;1557-1568.
9. Farese A.M., Casey D.B., Smith W.G., Vigneulle R.M., McKearn J.P., MacVittie T.J. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a non-human primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 19:2001;522-533.
10. S.P.S. Vadhan-Raj, J. Gano, M. Donato, C. Ramos, N. Papadopolous, A. Burgess, C. Plager, C. Baum, J. Sherman, R. Champlin, H.E. Broxmeyer, R.S. Benjamin, Blood 90, Supplement 1, Part 1 (1997) p. 212a.
11. Nabholtz J.M., Cantin J., Chang J., Guevin R., Patel R., Tkaczuk K., Vodvarka P., Lindsay M.A., Reese D., Riva A., Mackey J. Phase III trial comparing granulocyte colony-stimulating factor to Leridistim in prevention of neutropenic complications. Clin. Breast Cancer. 3:2002;268-275.
12. van Gils F.C., Budel L.M., Burger H., van Leen R.W., Lowenberg B., Wagemaker G. Interleukin-3 (IL-3) receptors in rhesus monkey bone marrow cells: species specificity of human IL-3. Exp. Hematol. 22:1994;248-255.
13. N.V. Katre, Lipid-based multivesicular carriers for sustained delivery of therapeutic proteins and peptides, Biopharm. Lab. March Supplement (2001) 8-11.
14. Katre N.V., Asherman J., Schaefer H., Hora M. Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I). J. Pharm. Sci. 87:1998;1341-1346.
15. Ye Q., Asherman J., Stevenson M., Brownson E., Katre N.V. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J. Controlled Release. 64:2000;155-166.
16. Ramprasad M.P., Anantharamaiah G.M., Garber D.W., Katre N.V. Sustained-delivery of an apolipoproteinE-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels. J. Controlled Release. 79:2002;207-218.
17. Kim S., Turker M.S., Chi E.Y., Sela S., Martin G.M. Preparation of multivesicular liposomes. Biochim. Biophys. Acta. 728:1983;339-348.
18. Howell S.B. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam™ Technology. Cancer J. 7:2001;219-227.
19. Dijkstra J., Mellors J.W., Ryan J.L., Szoka F.C. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J. Immunol. 138:1987;2663-2670.
20. Farese A.M., Casey D.B., Vigneulle R.M., Siegel N.R., Finn R.F., Klover J.A., Smith W.G., McKearn J.P., MacVittie T.J. A single dose of PEGylated Leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells. 19:2001;514-521.
21. Ellena J.F., Cafiso D.S., Langston M., Solis R.M., Sankaram M. Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv. 6:1999;97-106.
22. Katre N.V. The conjugation of proteins with polyethylene glycol and other polymers. Adv. Drug Deliv. Rev. 10:1993;91-114.
23. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22:2001;405-417.
24. Knauf M.J., Bell D.P., Hirtzer P., Luo Z.P., Young J.D., Katre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 263:1988;15064-15070.
25. R. Hills, R. Finn, P. Nicastro, T. Thurman, K. Thayer, W. Durham, J. Klover, W. Smith, N. Siegel, PEGylated Leridistim: multiple approaches to lead selection, Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials, Volume 1 (2001) Abstract #6157.
26. Molineux G., Kinstler O., Briddell B., Hartley C., McElroy P., Ulich T., Lockbaum P., Miller-Messana M.A., Gardner S., Hunt T., Schwab G. A new form of Filgrastim with sustained duration in vivo. Exp. Hematol. 27:1999;1724-1734.
27. Bowen S., Tare N., Inoue T., Yamasaki M., Okabe M., Horii I., Eliason J.F. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 27:1999;425-432.
28. Lord B.I., Woolford L.B., Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim or filgrastim SD/01. Clin. Cancer Res. 7:2001;2085-2090.
29. Sun Y.N., Lee H.J., Almon R.R., Jusko W.J. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. J. Pharmacol. Exp. Ther. 289:1999;1523-1532.